

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria VA, on the date shown below.

Dated:

8/11/03

Signature:

Katherine L. Neville

Docket No.: 27866/37524
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gallatin et al

Application No.: 09/891,943

Group Art Unit: 1644

Filed: June 26, 2001

Examiner: P. Gambel

For: Novel Human Beta-2 Alpha Integrin subunit

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is in response to an outstanding Office Action (hereinafter, the "Office Action"), mailed February 11, 2003, in the above-mentioned application. In the Office Action, the Examiner raised objections to the specification, e.g., correction of formal drawings, amendment to the title of the application, update of the priority claims, and omission of sequence identifiers. In the Office Action, the examiner rejected claims 11-14 under 35 USC § 112, first paragraph, for asserted lack of enablement and under 35 USC § 112, second paragraph, for asserted indefiniteness. The Examiner also rejected claims 11-14 under 35 USC 102 (b) as allegedly being anticipated by Gallatin *et al.*, US Patent No. 5,437,958 (hereinafter "Gallatin").

RECEIVED
AUG 18 2003
TECH CENTER 1600/2900